Table 4

Sensitivity analysis


Change in Outcome
 CER
Parameter
 Net Cost
 LYG
 QALY
 Cost/LYG
 Cost/QALY
Base values
 £2,066
 0.32
 0.37
 £6,772
 £5,609
Age (mean)




46.5 years
 £2,531
 0.34
 0.45
 £7,476
 £5,589
82.5 years
 £718
 0.14
 0.12
 £5,303
 £5,804
Cost of complications




+20%
 £1,973
 0.32
 0.37
 £6,213
 £5,357
-20%
 £2,159
 0.32
 0.37
 £6,799
 £5,861
Duration of disease before oral agent prescribed




5 years
 £2,101
 0.27
 0.33
 £7,680
 £6,320
10 years
 £1,971
 0.31
 0.35
 £6,260
 £5,553
Utilities




+20%
 £2,066
 0.32
 0.36
 £6,506
 £5,807
-20%
 £2,066
 0.32
 0.38
 £6,506
 £5,426
Race




100% Caucasian
 £2,105
 0.31
 0.36
 £6,686
 £5,771
HbA1c level




HbA1c before prescription = 9.4%
 £1,782
 0.37
 0.42
 £4,784
 £4,287
Metformin = 8.6%




Combination = 7.9%




HbA1c before prescription = 7.9%
 £2,184
 0.28
 0.34
 £7,904
 £6,516
Metformin = 7.1%




Combination = 6.4%




HbA1c upward drift




Metformin = 1.5%; Combination = 0%
 £1,478
 0.54
 0.65
 £2,761
 £2,272
Metformin = 0%; Combination = 0%
 £2,307
 0.28
 0.31
 £8,336
 £7,338
HbA1c drift delay




Metformin = 0 years; Combination = 1 year
 £1,987
 0.35
 0.41
 £5,715
 £4,870
Discount




Cost = 3%; Benefit = 3%
 £2,420
 0.26
 0.30
 £9,319
 £8,058
Cost = 6%; Benefit = 6%
 £2,066
 0.18
 0.21
 £11,369
 £9,888
Cost = 6%; Benefit = 0%
 £2,066
 0.39
 0.46
 £5,237
 £4,500

Ward et al. Cost Effectiveness and Resource Allocation 2004 2:2   doi:10.1186/1478-7547-2-2

Open Data